Alvotech Stock Price, News & Analysis

Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, has announced its participation in the upcoming Jefferies Global Healthcare Conference 2025 in New York. The event will take place from June 3-5, 2025, where the company's management team will conduct one-on-one meetings. Dr. Balaji Prasad, Chief Strategy Officer, will deliver a business update presentation on June 5, 2025, from 10:30-11:00 am EDT. The presentation will be accessible via live video webcast on Alvotech's investor relations website, with a replay available for 90 days following the event.

Alvotech (NASDAQ: ALVO) and Advanz Pharma have expanded their strategic partnership to include three additional biosimilar candidates in Europe. The new agreement covers biosimilars to Ilaris® (canakinumab) for inflammatory diseases, Kesimpta® (ofatumumab) for multiple sclerosis, and an undisclosed candidate. The deal includes development and commercial milestones worth up to $180 million, plus revenue sharing. This expansion builds on their 2023 partnership covering eight other biosimilars. Alvotech will handle development and supply, while Advanz Pharma will manage registration and commercialization across the European Economic Area, UK, and Switzerland. The total addressable market for all partnered biosimilars in the covered regions is estimated at $13.8 billion.

Alvotech (ALVO) has announced its upcoming Annual General Meeting (AGM) scheduled for June 25, 2025, at 09:00 a.m. CEST. The meeting will take place at Arendt & Medernach's premises in Luxembourg. Shareholders can access the complete agenda and meeting materials through Alvotech's investor relations website. The company has provided a dedicated contact for investor relations inquiries through Benedikt Stefansson, VP.

Alvogen Lux Holdings S.ár.l., Alvotech's second-largest shareholder, has acquired 95,000 shares of Alvotech (ALVO) at ISK 1,260 per share on May 20, 2025. The transaction was reported to the Luxembourg Commission de Surveillance du Secteur Financier (CSSF). Alvogen Lux Holdings' ownership structure consists of CVC (40%), Aztiq (30%), and Temasek (20%) as its largest shareholders.

Alvotech (NASDAQ: ALVO) has signed an agreement with DNB Carnegie Investment Bank AB to provide liquidity services for its Swedish Depository Receipts (SDRs) trading on Nasdaq Stockholm. Starting May 20, 2025, DNB Carnegie will act as a liquidity provider, continuously quoting prices for Alvotech's SDRs in compliance with Nasdaq Stockholm's minimum requirements. The primary objective is to enhance SDR liquidity and minimize the spread between buying and selling prices.

Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has commenced trading on Nasdaq Stockholm on May 19, 2025. The company offered Swedish Depository Receipts (SDRs) at SEK 87.51 per SDR, which was multiple times oversubscribed with over 3,000 individual subscribers. The offering included 441,600 SDRs, generating gross proceeds of approximately SEK 39 million. Each SDR represents one ordinary share. This listing expands Alvotech's presence to three markets: Nasdaq Stockholm, Nasdaq Global Market (US), and Nasdaq Iceland Main Market. The move follows Alvotech's recent acquisition of Xbrane Biopharma's R&D operations at the Karolinska life-science hub in Sweden, expected to close in early June 2025. The company aims to strengthen its Nordic presence, improve capital access, and attract broader institutional and retail investors.

Alvotech (NASDAQ: ALVO) has announced the successful completion of its Swedish Depository Receipts (SDRs) offering for its Nasdaq Stockholm listing. The offering, which ran from May 9-16, 2025, was multiple times oversubscribed and attracted over 3,000 new shareholders. The final SDR price was set at SEK 87.51, representing a 10% discount to the volume-weighted average share price on Nasdaq Iceland. The offering included 441,600 SDRs, generating gross proceeds of approximately SEK 39 million. Trading on Nasdaq Stockholm will commence on May 19, 2025, under the ticker "ALVO SDB". The listing follows Alvotech's recent acquisition of Xbrane Biopharma's R&D operations at the Karolinska life-science hub in Sweden, aimed at expanding its R&D capabilities and accessing a broader talent pool in the Swedish life-science sector.

Alvotech (ALVO) reported that Richard Davies, Deputy Chairman of the Board of Directors, has acquired 19,988 shares at a price of $10.18 per share on May 14, 2025. The total transaction value amounts to approximately $203,477. The transaction was filed with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) as part of the required disclosure for transactions of managers and closely associated persons.

Alvogen Lux Holdings S.ár.l., Alvotech's (ALVO) second-largest shareholder, has acquired 210,000 shares at ISK 1,277.38 per share. The transaction was reported through a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF). Alvogen Lux Holdings' ownership structure consists of CVC (40%), Aztiq (30%), and Temasek (20%) as its largest shareholders.